❌

Normal view

Received — 23 January 2026 ⏭ Favourites
  • ✇MIT Technology Review
  • “Dr. Google” had its issues. Can ChatGPT Health do better? Grace Huckins
    For the past two decades, there’s been a clear first step for anyone who starts experiencing new medical symptoms: Look them up online. The practice was so common that it gained the pejorative moniker “Dr. Google.” But times are changing, and many medical-information seekers are now using LLMs. According to OpenAI, 230 million people ask ChatGPT health-related queries each week.  That’s the context around the launch of OpenAI’s new ChatGPT Health product, which debuted earlier this month.
     
  • 🏷️
  • ↗️

“Dr. Google” had its issues. Can ChatGPT Health do better?

✇MIT Technology Review
By: Grace Huckins
23 January 2026 at 01:38

For the past two decades, there’s been a clear first step for anyone who starts experiencing new medical symptoms: Look them up online. The practice was so common that it gained the pejorative moniker “Dr. Google.” But times are changing, and many medical-information seekers are now using LLMs. According to OpenAI, 230 million people ask ChatGPT health-related queries each week. 

That’s the context around the launch of OpenAI’s new ChatGPT Health product, which debuted earlier this month. It landed at an inauspicious time: Two days earlier, the news website SFGate had broken the story of Sam Nelson, a teenager who died of an overdose last year after extensive conversations with ChatGPT about how best to combine various drugs. In the wake of both pieces of news, multiple journalists questioned the wisdom of relying for medical advice on a tool that could cause such extreme harm.

Though ChatGPT Health lives in a separate sidebar tab from the rest of ChatGPT, it isn’t a new model. It’s more like a wrapper that provides one of OpenAI’s preexisting models with guidance and tools it can use to provide health advice—including some that allow it to access a user’s electronic medical records and fitness app data, if granted permission. There’s no doubt that ChatGPT and other large language models can make medical mistakes, and OpenAI emphasizes that ChatGPT Health is intended as an additional support, rather than a replacement for one’s doctor. But when doctors are unavailable or unable to help, people will turn to alternatives. 

Some doctors see LLMs as a boon for medical literacy. The average patient might struggle to navigate the vast landscape of online medical information—and, in particular, to distinguish high-quality sources from polished but factually dubious websites—but LLMs can do that job for them, at least in theory. Treating patients who had searched for their symptoms on Google required “a lot of attacking patient anxiety [and] reducing misinformation,” says Marc Succi, an associate professor at Harvard Medical School and a practicing radiologist. But now, he says, “you see patients with a college education, a high school education, asking questions at the level of something an early med student might ask.”

The release of ChatGPT Health, and Anthropic’s subsequent announcement of new health integrations for Claude, indicate that the AI giants are increasingly willing to acknowledge and encourage health-related uses of their models. Such uses certainly come with risks, given LLMs’ well-documented tendencies to agree with users and make up information rather than admit ignorance. 

But those risks also have to be weighed against potential benefits. There’s an analogy here to autonomous vehicles: When policymakers consider whether to allow Waymo in their city, the key metric is not whether its cars are ever involved in accidents but whether they cause less harm than the status quo of relying on human drivers. If Dr. ChatGPT is an improvement over Dr. Google—and early evidence suggests it may be—it could potentially lessen the enormous burden of medical misinformation and unnecessary health anxiety that the internet has created.

Pinning down the effectiveness of a chatbot such as ChatGPT or Claude for consumer health, however, is tricky. “It’s exceedingly difficult to evaluate an open-ended chatbot,” says Danielle Bitterman, the clinical lead for data science and AI at the Mass General Brigham health-care system. Large language models score well on medical licensing examinations, but those exams use multiple-choice questions that don’t reflect how people use chatbots to look up medical information.

Sirisha Rambhatla, an assistant professor of management science and engineering at the University of Waterloo, attempted to close that gap by evaluating how GPT-4 responded to licensing exam questions when it did not have access to a list of possible answers. Medical experts who evaluated the responses scored only about half of them as entirely correct. But multiple-choice exam questions are designed to be tricky enough that the answer options don’t give them entirely away, and they’re still a pretty distant approximation for the sort of thing that a user would type into ChatGPT.

A different study, which tested GPT-4o on more realistic prompts submitted by human volunteers, found that it answered medical questions correctly about 85% of the time. When I spoke with Amulya Yadav, an associate professor at Pennsylvania State University who runs the Responsible AI for Social Emancipation Lab and led the study, he made it clear that he wasn’t personally a fan of patient-facing medical LLMs. But he freely admits that, technically speaking, they seem up to the task—after all, he says, human doctors misdiagnose patients 10% to 15% of the time. “If I look at it dispassionately, it seems that the world is gonna change, whether I like it or not,” he says.

For people seeking medical information online, Yadav says, LLMs do seem to be a better choice than Google. Succi, the radiologist, also concluded that LLMs can be a better alternative to web search when he compared GPT-4’s responses to questions about common chronic medical conditions with the information presented in Google’s knowledge panel, the information box that sometimes appears on the right side of the search results.

Since Yadav’s and Succi’s studies appeared online, in the first half of 2025, OpenAI has released multiple new versions of GPT, and it’s reasonable to expect that GPT-5.2 would perform even better than its predecessors. But the studies do have important limitations: They focus on straightforward, factual questions, and they examine only brief interactions between users and chatbots or web search tools. Some of the weaknesses of LLMs—most notably their sycophancy and tendency to hallucinate—might be more likely to rear their heads in more extensive conversations and with people who are dealing with more complex problems. Reeva Lederman, a professor at the University of Melbourne who studies technology and health, notes that patients who don’t like the diagnosis or treatment recommendations that they receive from a doctor might seek out another opinion from an LLM—and the LLM, if it’s sycophantic, might encourage them to reject their doctor’s advice.

Some studies have found that LLMs will hallucinate and exhibit sycophancy in response to health-related prompts. For example, one study showed that GPT-4 and GPT-4o will happily accept and run with incorrect drug information included in a user’s question. In another, GPT-4o frequently concocted definitions for fake syndromes and lab tests mentioned in the user’s prompt. Given the abundance of medically dubious diagnoses and treatments floating around the internet, these patterns of LLM behavior could contribute to the spread of medical misinformation, particularly if people see LLMs as trustworthy.

OpenAI has reported that the GPT-5 series of models is markedly less sycophantic and prone to hallucination than their predecessors, so the results of these studies might not apply to ChatGPT Health. The company also evaluated the model that powers ChatGPT Health on its responses to health-specific questions, using their publicly available HeathBench benchmark. HealthBench rewards models that express uncertainty when appropriate, recommend that users seek medical attention when necessary, and refrain from causing users unnecessary stress by telling them their condition is more serious that it truly is. It’s reasonable to assume that the model underlying ChatGPT Health exhibited those behaviors in testing, though Bitterman notes that some of the prompts in HealthBench were generated by LLMs, not users, which could limit how well the benchmark translates into the real world.

An LLM that avoids alarmism seems like a clear improvement over systems that have people convincing themselves they have cancer after a few minutes of browsing. And as large language models, and the products built around them, continue to develop, whatever advantage Dr. ChatGPT has over Dr. Google will likely grow. The introduction of ChatGPT Health is certainly a move in that direction: By looking through your medical records, ChatGPT can potentially gain far more context about your specific health situation than could be included in any Google search, although numerous experts have cautioned against giving ChatGPT that access for privacy reasons.

Even if ChatGPT Health and other new tools do represent a meaningful improvement over Google searches, they could still conceivably have a negative effect on health overall. Much as automated vehicles, even if they are safer than human-driven cars, might still prove a net negative if they encourage people to use public transit less, LLMs could undermine users’ health if they induce people to rely on the internet instead of human doctors, even if they do increase the quality of health information available online.

Lederman says that this outcome is plausible. In her research, she has found that members of online communities centered on health tend to put their trust in users who express themselves well, regardless of the validity of the information they are sharing. Because ChatGPT communicates like an articulate person, some people might trust it too much, potentially to the exclusion of their doctor. But LLMs are certainly no replacement for a human doctor—at least not yet.

Correction 1/26: A previous version of this story incorrectly referred to the version of ChatGPT that Rambhatla evaluated. It was GPT-4, not GPT-4o.

The Responsibility Vacuum: Organizational Failure in Scaled Agent Systems

✇cs.AI, q-bio.NC updates on arXiv.org
By: Oleg Romanchuk · Roman Bondar
22 January 2026 at 13:00
arXiv:2601.15059v1 Announce Type: new Abstract: Modern CI/CD pipelines integrating agent-generated code exhibit a structural failure in responsibility attribution. Decisions are executed through formally correct approval processes, yet no entity possesses both the authority to approve those decisions and the epistemic capacity to meaningfully understand their basis. We define this condition as responsibility vacuum: a state in which decisions occur, but responsibility cannot be attributed because authority and verification capacity do not coincide. We show that this is not a process deviation or technical defect, but a structural property of deployments where decision generation throughput exceeds bounded human verification capacity. We identify a scaling limit under standard deployment assumptions, including parallel agent generation, CI-based validation, and individualized human approval gates. Beyond a throughput threshold, verification ceases to function as a decision criterion and is replaced by ritualized approval based on proxy signals. Personalized responsibility becomes structurally unattainable in this regime. We further characterize a CI amplification dynamic, whereby increasing automated validation coverage raises proxy signal density without restoring human capacity. Under fixed time and attention constraints, this accelerates cognitive offloading in the broad sense and widens the gap between formal approval and epistemic understanding. Additional automation therefore amplifies, rather than mitigates, the responsibility vacuum. We conclude that unless organizations explicitly redesign decision boundaries or reassign responsibility away from individual decisions toward batch- or system-level ownership, responsibility vacuum remains an invisible but persistent failure mode in scaled agent deployments.

Guardrails for trust, safety, and ethical development and deployment of Large Language Models (LLM)

✇cs.AI, q-bio.NC updates on arXiv.org
By: Anjanava Biswas · Wrick Talukdar
22 January 2026 at 13:00
arXiv:2601.14298v1 Announce Type: cross Abstract: The AI era has ushered in Large Language Models (LLM) to the technological forefront, which has been much of the talk in 2023, and is likely to remain as such for many years to come. LLMs are the AI models that are the power house behind generative AI applications such as ChatGPT. These AI models, fueled by vast amounts of data and computational prowess, have unlocked remarkable capabilities, from human-like text generation to assisting with natural language understanding (NLU) tasks. They have quickly become the foundation upon which countless applications and software services are being built, or at least being augmented with. However, as with any groundbreaking innovations, the rise of LLMs brings forth critical safety, privacy, and ethical concerns. These models are found to have a propensity to leak private information, produce false information, and can be coerced into generating content that can be used for nefarious purposes by bad actors, or even by regular users unknowingly. Implementing safeguards and guardrailing techniques is imperative for applications to ensure that the content generated by LLMs are safe, secure, and ethical. Thus, frameworks to deploy mechanisms that prevent misuse of these models via application implementations is imperative. In this study, wepropose a Flexible Adaptive Sequencing mechanism with trust and safety modules, that can be used to implement safety guardrails for the development and deployment of LLMs.

An Optimized Decision Tree-Based Framework for Explainable IoT Anomaly Detection

✇cs.AI, q-bio.NC updates on arXiv.org
By: Ashikuzzaman · Md. Shawkat Hossain · Jubayer Abdullah Joy · Md Zahid Akon · Md Manjur Ahmed · Md. Naimul Islam
22 January 2026 at 13:00
arXiv:2601.14305v1 Announce Type: cross Abstract: The increase in the number of Internet of Things (IoT) devices has tremendously increased the attack surface of cyber threats thus making a strong intrusion detection system (IDS) with a clear explanation of the process essential towards resource-constrained environments. Nevertheless, current IoT IDS systems are usually traded off with detection quality, model elucidability, and computational effectiveness, thus the deployment on IoT devices. The present paper counteracts these difficulties by suggesting an explainable AI (XAI) framework based on an optimized Decision Tree classifier with both local and global importance methods: SHAP values that estimate feature attribution using local explanations, and Morris sensitivity analysis that identifies the feature importance in a global view. The proposed system attains the state of art on the test performance with 99.91% accuracy, F1-score of 99.51% and Cohen Kappa of 0.9960 and high stability is confirmed by a cross validation mean accuracy of 98.93%. Efficiency is also enhanced in terms of computations to provide faster inferences compared to those that are generalized in ensemble models. SrcMac has shown as the most significant predictor in feature analyses according to SHAP and Morris methods. Compared to the previous work, our solution eliminates its major drawback lack because it allows us to apply it to edge devices and, therefore, achieve real-time processing, adhere to the new regulation of transparency in AI, and achieve high detection rates on attacks of dissimilar classes. This combination performance of high accuracy, explainability, and low computation make the framework useful and reliable as a resource-constrained IoT security problem in real environments.

Towards Execution-Grounded Automated AI Research

✇cs.AI, q-bio.NC updates on arXiv.org
By: Chenglei Si · Zitong Yang · Yejin Choi · Emmanuel Cand\`es · Diyi Yang · Tatsunori Hashimoto
22 January 2026 at 13:00
arXiv:2601.14525v1 Announce Type: cross Abstract: Automated AI research holds great potential to accelerate scientific discovery. However, current LLMs often generate plausible-looking but ineffective ideas. Execution grounding may help, but it is unclear whether automated execution is feasible and whether LLMs can learn from the execution feedback. To investigate these, we first build an automated executor to implement ideas and launch large-scale parallel GPU experiments to verify their effectiveness. We then convert two realistic research problems - LLM pre-training and post-training - into execution environments and demonstrate that our automated executor can implement a large fraction of the ideas sampled from frontier LLMs. We analyze two methods to learn from the execution feedback: evolutionary search and reinforcement learning. Execution-guided evolutionary search is sample-efficient: it finds a method that significantly outperforms the GRPO baseline (69.4% vs 48.0%) on post-training, and finds a pre-training recipe that outperforms the nanoGPT baseline (19.7 minutes vs 35.9 minutes) on pre-training, all within just ten search epochs. Frontier LLMs often generate meaningful algorithmic ideas during search, but they tend to saturate early and only occasionally exhibit scaling trends. Reinforcement learning from execution reward, on the other hand, suffers from mode collapse. It successfully improves the average reward of the ideator model but not the upper-bound, due to models converging on simple ideas. We thoroughly analyze the executed ideas and training dynamics to facilitate future efforts towards execution-grounded automated AI research.

Multimodal system for skin cancer detection

✇cs.AI, q-bio.NC updates on arXiv.org
By: Volodymyr Sydorskyi · Igor Krashenyi · Oleksii Yakubenko
22 January 2026 at 13:00
arXiv:2601.14822v1 Announce Type: cross Abstract: Melanoma detection is vital for early diagnosis and effective treatment. While deep learning models on dermoscopic images have shown promise, they require specialized equipment, limiting their use in broader clinical settings. This study introduces a multi-modal melanoma detection system using conventional photo images, making it more accessible and versatile. Our system integrates image data with tabular metadata, such as patient demographics and lesion characteristics, to improve detection accuracy. It employs a multi-modal neural network combining image and metadata processing and supports a two-step model for cases with or without metadata. A three-stage pipeline further refines predictions by boosting algorithms and enhancing performance. To address the challenges of a highly imbalanced dataset, specific techniques were implemented to ensure robust training. An ablation study evaluated recent vision architectures, boosting algorithms, and loss functions, achieving a peak Partial ROC AUC of 0.18068 (0.2 maximum) and top-15 retrieval sensitivity of 0.78371. Results demonstrate that integrating photo images with metadata in a structured, multi-stage pipeline yields significant performance improvements. This system advances melanoma detection by providing a scalable, equipment-independent solution suitable for diverse healthcare environments, bridging the gap between specialized and general clinical practices.

Automated Rubrics for Reliable Evaluation of Medical Dialogue Systems

✇cs.AI, q-bio.NC updates on arXiv.org
By: Yinzhu Chen · Abdine Maiga · Hossein A. Rahmani · Emine Yilmaz
22 January 2026 at 13:00
arXiv:2601.15161v1 Announce Type: cross Abstract: Large Language Models (LLMs) are increasingly used for clinical decision support, where hallucinations and unsafe suggestions may pose direct risks to patient safety. These risks are particularly challenging as they often manifest as subtle clinical errors that evade detection by generic metrics, while expert-authored fine-grained rubrics remain costly to construct and difficult to scale. In this paper, we propose a retrieval-augmented multi-agent framework designed to automate the generation of instance-specific evaluation rubrics. Our approach grounds evaluation in authoritative medical evidence by decomposing retrieved content into atomic facts and synthesizing them with user interaction constraints to form verifiable, fine-grained evaluation criteria. Evaluated on HealthBench, our framework achieves a Clinical Intent Alignment (CIA) score of 60.12%, a statistically significant improvement over the GPT-4o baseline (55.16%). In discriminative tests, our rubrics yield a mean score delta ($\mu_{\Delta} = 8.658$) and an AUROC of 0.977, nearly doubling the quality separation achieved by GPT-4o baseline (4.972). Beyond evaluation, our rubrics effectively guide response refinement, improving quality by 9.2% (from 59.0% to 68.2%). This provides a scalable and transparent foundation for both evaluating and improving medical LLMs. The code is available at https://anonymous.4open.science/r/Automated-Rubric-Generation-AF3C/.

Manalyzer: End-to-end Automated Meta-analysis with Multi-agent System

✇cs.AI, q-bio.NC updates on arXiv.org
By: Wanghan Xu · Wenlong Zhang · Fenghua Ling · Ben Fei · Yusong Hu · Runmin Ma · Bo Zhang · Fangxuan Ren · Jintai Lin · Wanli Ouyang · Lei Bai
22 January 2026 at 13:00
arXiv:2505.20310v2 Announce Type: replace Abstract: Meta-analysis is a systematic research methodology that synthesizes data from multiple existing studies to derive comprehensive conclusions. This approach not only mitigates limitations inherent in individual studies but also facilitates novel discoveries through integrated data analysis. Traditional meta-analysis involves a complex multi-stage pipeline including literature retrieval, paper screening, and data extraction, which demands substantial human effort and time. However, while LLM-based methods can accelerate certain stages, they still face significant challenges, such as hallucinations in paper screening and data extraction. In this paper, we propose a multi-agent system, Manalyzer, which achieves end-to-end automated meta-analysis through tool calls. The hybrid review, hierarchical extraction, self-proving, and feedback checking strategies implemented in Manalyzer significantly alleviate these two hallucinations. To comprehensively evaluate the performance of meta-analysis, we construct a new benchmark comprising 729 papers across 3 domains, encompassing text, image, and table modalities, with over 10,000 data points. Extensive experiments demonstrate that Manalyzer achieves significant performance improvements over the LLM baseline in multi meta-analysis tasks. Project page: https://black-yt.github.io/meta-analysis-page/ .

Towards AI Transparency and Accountability: A Global Framework for Exchanging Information on AI Systems

✇cs.AI, q-bio.NC updates on arXiv.org
By: Warren Buckley · Adrian Byrne · Nicholas Perello · Cyrus Cousins · Taha Yasseri · Yair Zick · Przemyslaw Grabowicz
22 January 2026 at 13:00
arXiv:2307.13658v3 Announce Type: replace-cross Abstract: We propose that future AI transparency and accountability regulations are based on an open global standard for exchanging information about AI systems, which allows co-existence of potentially conflicting local regulations. Then, we discuss key components of a lightweight and effective AI transparency and/or accountability regulation. To prevent overregulation, the proposed approach encourages collaboration between regulators and industry to create a scalable and cost-efficient mutually beneficial solution. This includes using automated assessments and benchmarks with results transparently communicated through AI cards in an open AI register to facilitate meaningful public comparisons of competing AI systems. Such AI cards should report standardized measures tailored to the specific high-risk applications of AI systems and could be used for conformity assessments under AI transparency and accountability policies such as the European Union's AI Act.

PPGFlowECG: Latent Rectified Flow with Cross-Modal Encoding for PPG-Guided ECG Generation and Cardiovascular Disease Detection

✇cs.AI, q-bio.NC updates on arXiv.org
By: Xiaocheng Fang · Jiarui Jin · Haoyu Wang · Che Liu · Jieyi Cai · Yujie Xiao · Guangkun Nie · Bo Liu · Shun Huang · Hongyan Li · Shenda Hong
22 January 2026 at 13:00
arXiv:2509.19774v2 Announce Type: replace-cross Abstract: Electrocardiography (ECG) is the clinical gold standard for cardiovascular disease (CVD) assessment, yet continuous monitoring is constrained by the need for dedicated hardware and trained personnel. Photoplethysmography (PPG) is ubiquitous in wearable devices and readily scalable, but it lacks electrophysiological specificity, limiting diagnostic reliability. While generative methods aim to translate PPG into clinically useful ECG signals, existing approaches are limited by the misalignment of physiological semantics in generative models and the complexity of modeling in high-dimensional signals. To address these limitations, we propose PPGFlowECG, a two-stage framework that aligns PPG and ECG in a shared latent space using the CardioAlign Encoder and then synthesizes ECGs with latent rectified flow. We further provide a formal analysis of this coupling, showing that the CardioAlign Encoder is necessary to guarantee stable and semantically consistent ECG synthesis under our formulation. Extensive experiments on four datasets demonstrate improved synthesis fidelity and downstream diagnostic utility. These results indicate that PPGFlowECG supports scalable, wearable-first CVD screening when standard ECG acquisition is unavailable.

Large-scale spatial profiling of the tumor microenvironment

✇Cell
By: Aaron Kilgallon · Rafael Tubelleza · Arutha Kulasinghe
22 January 2026 at 08:00
Multiplex immunofluorescence proteomics is a powerful method in spatial biology to decipher cell types, states, and architecture in tissues. In this issue of Cell, Valanarasu et al. develop GigaTIME, an expansive population-scale analysis of the tumor immune microenvironment of over 14,000 patients across 24 cancer types, enabling clinical discovery and patient stratification.

Large language models improve transferability of electronic health record-based predictions across countries and coding systems

✇npj Digital Medicine
By: Matthias Kirchler · Matteo Ferro · Veronica Lorenzini · Robin P. van de Water · Andrea Ganna · Christoph Lippert
22 January 2026 at 08:00

npj Digital Medicine, Published online: 22 January 2026; doi:10.1038/s41746-026-02363-5

Large language models improve transferability of electronic health record-based predictions across countries and coding systems

Multimodal AI generates virtual population for tumor microenvironment modeling

✇Cell
By: Jeya Maria Jose Valanarasu · Hanwen Xu · Naoto Usuyama · Chanwoo Kim · Cliff Wong · Peniel Argaw · Racheli Ben Shimol · Angela Crabtree · Kevin Matlock · Alexandra Q. Bartlett · Jaspreet Bagga · Yu Gu · Sheng Zhang · Tristan Naumann · Bernard A. Fox · Bill Wright · Ari Robicsek · Brian Piening · Carlo Bifulco · Sheng Wang · Hoifung Poon
9 December 2025 at 08:00
GigaTIME leverages multimodal AI to generate virtual multiplex immunofluorescence (mIF) profiles from standard H&E slides, enabling comprehensive tumor immune microenvironment modeling across a large (>14,000) and diverse patient population. This virtual approach unlocks new opportunities for large-scale clinical discoveries that were previously hindered by the scarcity of mIF data.
Received — 22 January 2026 ⏭ Favourites
  • ✇Latest Science News -- ScienceDaily
  • A simple blood test mismatch linked to kidney failure and death
    A major global study suggests that a hidden mismatch between two common blood tests could quietly signal serious trouble ahead. When results from creatinine and cystatin C—two markers used to assess kidney health—don’t line up, the risk of kidney failure, heart disease, and even death appears to rise sharply. Researchers found that this gap is especially common among hospitalized and older patients, and that relying on just one test may miss early warning signs.
     
  • 🏷️
  • ↗️

A simple blood test mismatch linked to kidney failure and death

✇Latest Science News -- ScienceDaily
22 January 2026 at 01:19
A major global study suggests that a hidden mismatch between two common blood tests could quietly signal serious trouble ahead. When results from creatinine and cystatin C—two markers used to assess kidney health—don’t line up, the risk of kidney failure, heart disease, and even death appears to rise sharply. Researchers found that this gap is especially common among hospitalized and older patients, and that relying on just one test may miss early warning signs.
  • ✇STAT
  • STAT+: OpenEvidence raises $250 million, doubling its valuation Mario Aguilar
    OpenEvidence, maker of a popular chatbot that helps doctors search clinical evidence, on Wednesday announced $250 million in new funding. The new round led by Thrive Capital and DST Global values OpenEvidence at $12 billion, and the company has announced $735 million in funding in the last 12 months. OpenEvidence is free to use by any clinician with a national provider identifier number. The company’s primary business model is advertising shown to clinicians.  Founded in 2022, OpenEvidence
     
  • 🏷️
  • ↗️

STAT+: OpenEvidence raises $250 million, doubling its valuation

✇STAT
By: Mario Aguilar
21 January 2026 at 23:38

OpenEvidence, maker of a popular chatbot that helps doctors search clinical evidence, on Wednesday announced $250 million in new funding.

The new round led by Thrive Capital and DST Global values OpenEvidence at $12 billion, and the company has announced $735 million in funding in the last 12 months. OpenEvidence is free to use by any clinician with a national provider identifier number. The company’s primary business model is advertising shown to clinicians. 

Founded in 2022, OpenEvidence is one of the most prominent and best-funded companies from a wave of health artificial intelligence companies that emerged since the widespread availability of large language models. Reflecting on the eye-popping fundraising for health AI, a Silicon Valley Bank report released earlier in January raised an eyebrow at the ability of companies like OpenEvidence to deliver on their stratospheric valuations with advertising and software-as-a-service business models. “It won’t be a surprise to see them tap the value of the data they’re already collecting” to offer more services to pharma or other customers, the authors wrote.

Continue to STAT+ to read the full story…

© Adobe

Research progress in diagnosis and treatment of pancreatic cancer with mismatch repair and microsatellite instability

✇(Multiomics OR Omics) AND (Pancreatic)
By: Hang Yin · Yong Liu · Jiatong Chen · Zhuang Li · Yue Pan · Feng Zhu
21 January 2026 at 19:00

Clin Transl Oncol. 2026 Jan 21. doi: 10.1007/s12094-025-04214-3. Online ahead of print.

ABSTRACT

Pancreatic cancer (PC), predominantly pancreatic ductal adenocarcinoma, remains one of the most lethal malignancies, largely due to late diagnosis and intrinsic resistance to conventional therapies. In recent years, mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) have emerged as clinically actionable biomarkers in a small but distinct subset of PC, accounting for approximately 1-2% of cases. These tumors display unique molecular characteristics, including a high prevalence of wild-type KRAS and TP53, elevated tumor mutational burden, and recurrent kinase fusions, which together confer enhanced immunogenicity and increased sensitivity to immune checkpoint inhibitors (ICIs). In addition to their therapeutic relevance, dMMR/MSI-H status has important diagnostic implications for the identification of Lynch syndrome-associated pancreatic cancers, informing genetic counseling and familial risk assessment. This review summarizes current understanding of the molecular basis of mismatch repair deficiency and microsatellite instability in PC, evaluates available diagnostic approaches such as immunohistochemistry, polymerase chain reaction, and next-generation sequencing, and discusses the prognostic and predictive significance of dMMR/MSI-H status. Emerging clinical evidence supporting the use of ICIs in selected patients across neoadjuvant, adjuvant, and advanced disease settings is also reviewed, along with challenges related to assay discordance, tumor heterogeneity, and immunotherapy resistance. Finally, future directions are highlighted, emphasizing the need for standardized testing algorithms, integration of multi-omics and spatial profiling technologies, and prospective clinical studies to optimize precision treatment strategies for this rare but clinically meaningful subtype of pancreatic cancer.

PMID:41563663 | DOI:10.1007/s12094-025-04214-3

Received — 21 January 2026 ⏭ Favourites
❌